NIH-supported study pits BPH devices against drugs
This article was originally published in The Gray Sheet
Medtronic and Urologix are among firms standing to benefit from a study comparing minimally invasive surgical treatment of benign prostatic hyperplasia (BPH) using transurethral needle ablation (TUNA) and transurethral microwave thermotherapy (TUMT) to drugs. Efficacy of the devices, offered by such firms as Medtronic (TUNA) and Urologix (TUMT), first approved by FDA in 1996, will be compared to a regimen of finasteride (Proscar) and the alpha-1 inhibitor doxazosin (Cardura). The study will be run by The Minimally Invasive Surgical Therapies (MIST) Consortium, supported in part by both firms, and will be funded by $15 mil. from the National Institute of Diabetes & Digestive & Kidney Diseases at NIH. The protocol will include three-to-five-year follow-up, roughly through July 2009, on more than 700 men with moderate to severe symptoms...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.